Genetic models for CNS inflammation

Nature Medicine

Volumn 7, Issue 2, 2001, Pages 161-166

  Owens, Trevor ^a   Wekerle, Hartmut ^b   Antel, Jack ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA INTERFERON; CHEMOKINE RECEPTOR CCR2; CYTOKINE; CYTOKINE INHIBITOR; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR P55R IMMUNOGLOBULIN G FUSION PROTEIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; ENCEPHALITIS; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT GENE; META ANALYSIS; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CLINICAL TRIALS; CYTOKINES; DEMYELINATING DISEASES; HUMANS; INTERFERON TYPE II; MODELS, GENETIC; MULTIPLE SCLEROSIS; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0035128996     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/84603     Document Type: Review

References (75)

1. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis
2. Walking through the forest of transgenic models of human disease
3. B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice
4. Tumor necrosis factor identified in multiple sclerosis brain
5. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
6. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta
7. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis
8. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines
9. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system
10. TNF-alpha transgenic and knockout models of CNS inflammation and degeneration
11. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor
12. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendrogliopathy
13. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1
14. Tumor necrosis factor: A master-regulator of leukocyte movement
15. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors
16. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
17. Cytokines and antibodies in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis
18. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice
19. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients
20. Lymphokines and immunoregulatory molecules in subacute sclerosing panencephalitis
21. Inflammatory cytokines in the brain: Does the CNS shape immune responses?
22. The effects of interferon-gamma on the central nervous system
23. Immune modulation within the brain: Recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma
24. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation
25. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats
26. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development
27. Primary demyelination in transgenic mice expressing interferon-gamma
28. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE
29. IFNγ enhances microglial reactions to hippocampal axonal degeneration
30. Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the central nervous system: Astrocytes fail to express major histocompatibility complex class I and II molecules
31. Dysmyelination in transgenic mice resulting from expression of class I histocompatibility molecules in oligodendrocytes
32. Major histocompatibility complex class I expression in oligodendrocytes induces hypomyelination in transgenic mice
33. Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities
34. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis
35. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis
36. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines
37. Interferon-gamma confers resistance to experimental allergic encephalomyelitis
38. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis
39. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma
40. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse
41. Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokines
42. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis
43. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
44. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine NS1/KC in oligodendrocytes
45. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1
46. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
47. Induction of experimental autoimmune encephalomyelitis in C578L/6 mice deficient in either the chemokine macrophage inflammatory protein-1 alpha or its CCR5 receptor
48. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice
49. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis
50. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: Roles of interleukin-10 in disease progression and recovery
51. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice
52. Specific immunotherapy: One size does not fit all
53. Late complications of immune deviation therapy in a nonhuman primate
54. Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice
55. Experimental allergic encephalomyelitis: Neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease
56. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1
57. Chronic overproduction of transforming growth factor-beta 1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice
58. Transgenic models to study the actions of cytokines in the central nervous system
59. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination
60. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis
61. An interleukin (IL-)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
62. Immunologic therapy of multiple sclerosis
63. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
64. Gamma-interferon induction in patients with chronic progressive MS
65. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo
66. Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors
67. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
68. Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment
69. The temporal importance of TNFα expression in the development of diabetes
70. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats
71. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12
72. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats
73. Differential induction of interleukin-12, intetleukin-18, and interleukin-1beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat
74. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis
75. C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system